CBD Life Sciences Inc. (OTCID:CBDL) is capturing strong investor attention following a recent high-profile interview with CEO Lisa Nelson on The Morning Show. Nelson highlighted the company's rapid expansion, new retail partnerships, and increased demand for its flagship therapeutic products. She outlined CBDL's disciplined growth strategy, product diversification across top wellness categories, and vision to transition from a regional brand to a national multi-vertical competitor. The interview comes as the global CBD market, currently valued at $14.6 billion, is projected to soar to $203.4 billion by 2034. Investors are closely watching CBDL as it accelerates product distribution and manufacturing, with real revenue traction and early-stage momentum. Watch the full Morning Show interview →
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cbd Life Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113522) on December 02, 2025, and is solely responsible for the information contained therein.
Comments